A part of Watch Media

MedWatchWednesday1 February 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
08/03/2021at 15:40

Bavarian Nordic still hopes to find financing for Covid-19 vaccine

In spite of positive preclinical data, Bavarian Nordic maintains that the firm itself will not finance further studies after the first phase I/II study. The company remains optimistic, however, about the prospects of finding capital for the vaccine from external sources.
Photo: Bavarian Nordic / PR
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN

While Bavarian Nordic's vaccine candidate against Covid-19 will soon enter into the first in-human phase I/II study, the Danish vaccine company is on the lookout for a partner to finance its further development and the process of taking the Covid-19 vaccine to market.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters

Get full access for you and your coworkers

Start a free company trial today

Related articles:

  • Photo: Sydbank/PR

    Analyst views clinical results as central to Bavarian Nordic's external financing

    For subscribers

  • Photo: Philip Davali/Ekstra Bladet, Philip Davali

    Bavarian Nordic presents new preclinical data for Covid-19 vaccine

    For subscribers

  • Photo: Manuel Balce Ceneta/AP/Ritzau Scanpix

    Biomarin awaits crucial approvals and flat growth in 2021

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Foto: Arnd Wiegmann/Reuters/Ritzau Scanpix
Pharma & biotech

Novartis beats Kesimpta sales expectations in Q4

Multiple sclerosis treatment Kesimpta, based on Genmab-developed ofatumumab, has generated more than analysts predicted in Q4’22.
  • Janssen's books disappointing sales of Genmab-developed Darzalex
  • Denmark rejects Janssen and Genmab drug twice in January

For subscribers

Foto: Andrew Kelly/Reuters/Ritzau Scanpix
Pharma & biotech

Analyst: Strong Novo Nordisk outlook should satisfy investors

For subscribers

Foto: Jens Dresling/Ritzau Scanpix
Pharma & biotech

Studies of Wegovy in higher-than-approved doses begin

For subscribers

Foto: Novo Nordisk
Pharma & biotech

Rare Disease business comes in slightly below expectations for Novo Nordisk

For subscribers

Foto: Stine Tidsvilde
Pharma & biotech

Novo Nordisk meets upgraded guidance, setting new revenue record

For subscribers

Foto: Novo Nordisk / Pr
Pharma & biotech

Novo Nordisk doubles obesity sales in 2022

For subscribers

Further reading

Photo: Robert Galbraith/Reuters/Ritzau Scanpix
Pharma & biotech

Amgen takes on Abbvie blockbuster Humira with unusual price plan

Abbvie’s multibillion-dollar generating anti-inflammatory drug, Humira, is about to face competition for the first time, as Amgen launches an almost identical product using an unconventional strategy.

For subscribers

Foto: Novo Nordisk / PR
Pharma & biotech

Novo Nordisk wins case in US appeals court

Three pharmaceutical firms, including Novo Nordisk, have won a case in a US appeals court, which agreed that the drugmakers can limit deliveries of federally discounted drugs.

For subscribers

Anders Hinsby (left), Thomas Kirkegaard Jensen, and Anders Vadsholt | Foto: Anne Bæk/Ritzau Scanpix
Pharma & biotech

Orphazyme trio founds new firm focused on neurology and rare diseases

Anders Hinsby, Anders Vadsholt, and Thomas Kirkegaard Jensen – all three key figures from now-defunct biotech company Orphazyme – have established a new company using experiences from the past.

For subscribers

Latest news

  • Novartis beats Kesimpta sales expectations in Q4 – 11:49
  • Analyst: Strong Novo Nordisk outlook should satisfy investors – 11:09
  • Studies of Wegovy in higher-than-approved doses begin – 10:01
  • Rare Disease business comes in slightly below expectations for Novo Nordisk – 09:48
  • Novo Nordisk meets upgraded guidance, setting new revenue record – 09:20
  • Novo Nordisk doubles obesity sales in 2022 – 08:54
  • Maersk and German start-up wants to enhance emission visibility for global e-trade – 08:27
  • Novo Nordisk predicts wide range for 2023 sales growth – 07:38
  • Pfizer hopes Covid-19 sales will increase in the long run – 31 Jan
  • Amgen takes on Abbvie blockbuster Humira with unusual price plan – 31 Jan
See all

Jobs

  • Regulatory Affairs Professional

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Application Manager

  • Sr. Director, Drug Safety Physician

  • Experienced Patent Counsel

  • Head of Regulatory Affairs Danmark

  • Lead Data Architect

  • Commercial Director

  • Application Manager

  • Clinical Operational Associate

  • Senior Regulatory Affairs Professional

See all jobs

Jobs

  • Regulatory Affairs Professional

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Application Manager

  • Sr. Director, Drug Safety Physician

  • Experienced Patent Counsel

  • Head of Regulatory Affairs Danmark

  • Lead Data Architect

  • Commercial Director

  • Application Manager

  • Clinical Operational Associate

  • Senior Regulatory Affairs Professional

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge